TY - JOUR
T1 - “Seeing” invisible volatile organic compound (VOC) marker of urinary bladder cancer
T2 - A development from bench to bedside prototype spectroscopic device
AU - Bhattacharyya, Neha
AU - Mukherjee, Dipanjan
AU - Singh, Soumendra
AU - Ghosh, Ria
AU - Karmakar, Saurav
AU - Mallick, Ankita
AU - Chattopadhyay, Arpita
AU - Mondal, Pulak
AU - Mondal, Tapan
AU - Bhattacharyya, Debasis
AU - Mallick, Asim Kumar
AU - Nabi, Ghulam
AU - Pal, Samir Kumar
N1 - Copyright:
© 2022 Elsevier B.V.
PY - 2022/12/15
Y1 - 2022/12/15
N2 - Urinary bladder cancer (UBC) is one of the most common cancers and has notoriously high risk of recurrence and mortality across the globe. Current clinical initial diagnostic approaches are either invasive or lacks sensitivity. In this study, an attempt has been made to invent a cost-effective, novel, portable diagnostic device based on the environmental sensitive fluorophores namely Nile Red (NR), Eosin Y (EY) and Rose Bengal (RB). They act as sensing agents for detecting volatile organic compounds (VOC) exclusively present in the urine sample of UBC patients and differentiate the UBC samples from the healthy control group. Upon exposure with a particular group of VOCs, a significant amount of increment in fluorescence intensities of NR, EY and RB were detected and recorded in our indigenously developed “NABIL” device. To check the performance of NABIL, the data collected from the device was compared with the conventional techniques by arranging a clinical trial with 21 healthy controls and 52 UBC patients. With the assistance of our analysis technique based on LabVIEW platform, very high sensitivity and accuracy from healthy controls have been achieved. For UBC patients, it shows impressive diagnostic results. In addition, depending on the sample processing mechanism, NABIL device can also reveal the grade of UBC and prognosis under treatment. Overall, this study contributes a novel, non-invasive, easy-to-use, inexpensive, real-time, accurate method for selectively UBC diagnosis, which can be useful for personalized care/diagnosis and postoperative surveillance, resulting in saving more lives.
AB - Urinary bladder cancer (UBC) is one of the most common cancers and has notoriously high risk of recurrence and mortality across the globe. Current clinical initial diagnostic approaches are either invasive or lacks sensitivity. In this study, an attempt has been made to invent a cost-effective, novel, portable diagnostic device based on the environmental sensitive fluorophores namely Nile Red (NR), Eosin Y (EY) and Rose Bengal (RB). They act as sensing agents for detecting volatile organic compounds (VOC) exclusively present in the urine sample of UBC patients and differentiate the UBC samples from the healthy control group. Upon exposure with a particular group of VOCs, a significant amount of increment in fluorescence intensities of NR, EY and RB were detected and recorded in our indigenously developed “NABIL” device. To check the performance of NABIL, the data collected from the device was compared with the conventional techniques by arranging a clinical trial with 21 healthy controls and 52 UBC patients. With the assistance of our analysis technique based on LabVIEW platform, very high sensitivity and accuracy from healthy controls have been achieved. For UBC patients, it shows impressive diagnostic results. In addition, depending on the sample processing mechanism, NABIL device can also reveal the grade of UBC and prognosis under treatment. Overall, this study contributes a novel, non-invasive, easy-to-use, inexpensive, real-time, accurate method for selectively UBC diagnosis, which can be useful for personalized care/diagnosis and postoperative surveillance, resulting in saving more lives.
KW - Non-invasive diagnosis
KW - Spectroscopic detection
KW - Urinary bladder cancer
KW - Volatile organic compounds
U2 - 10.1016/j.bios.2022.114764
DO - 10.1016/j.bios.2022.114764
M3 - Article
C2 - 36206669
AN - SCOPUS:85139359555
SN - 0956-5663
VL - 218
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
M1 - 114764
ER -